SSSimona Slezakova

Simona Slezakova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simona Slezakova has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacological interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units: a network meta-analysis

    by Ingrid Toews, Salman Hussain, John L Z Nyirenda, Maria A Willis, Lucia Kantorová, Simona Slezáková, Minyahil Tadesse Boltena, John Victor Peter, Luis Eduardo Santos Fontes, Miloslav Klugar, et al.

    Objectives To assess the efficacy and safety of pharmacological interventions for preventing upper gastrointestinal (GI) bleeding in people admitted to intensive care units (ICUs). Design and setting Systematic review and frequentist network meta-analysis using standard methodological procedures as recommended by Cochrane for screening of records, data extraction and analysis. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence. Participants Randomised controlled trials involving patients admitted to ICUs for longer than 24 hours were included. Search methods The Cochrane Gut Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and Latin American and Caribbean Health Science Information database (LILACS) databases were searched from August 2017 to March 2022. The search in MEDLINE was updated in April 2023. We also searched ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP). Main outcome measures The primary outcome was the prevention of clinically important upper GI bleeding. Results We included 123 studies with 46 996 participants. Cimetidine (relative risk (RR) 0.56, 95% CI 0.40 to 0.77, moderate certainty), ranitidine (RR 0.54, 95% CI 0.38 to 0.76, moderate certainty), antacids (RR 0.48, 95% CI 0.33 to 0.68, moderate certainty), sucralfate (RR 0.54, 95% CI 0.39 to 0.75, moderate certainty) and a combination of ranitidine and antacids (RR 0.13, 95% CI 0.03 to 0.62, moderate certainty) are likely effective in preventing upper GI bleeding. The effect of any intervention on the prevention of nosocomial pneumonia, all-cause mortality in the ICU or the hospital, duration of the stay in the ICU, duration of intubation and (serious) adverse events remains unclear. Conclusions Several interventions seem effective in preventing clinically important upper GI bleeding while there is limited evidence for other outcomes. Patient-relevant benefits and harms need to be assessed under consideration of the patients’ underlying conditions.


  • Gene polymorphisms and serum levels of mannose‐binding lectin in Czech patients with recurrent aphthous stomatitis: A case–control study

    by Pavla Izakovicova, Simona Slezakova, Zuzana Jiraskova Zakostelska, Jana Sistkova, Natalie Mlcuchova, Jirina Bartova, Jitka Petanova, Pavel Kuklinek, Antonin Fassmann, Ladislav Dusek, et al.

    Background: Recurrent aphthous stomatitis is one of the most prevalent oral mucosal immunological diseases. A recent case–control study in the Egyptian population suggested that single nucleotide polymorphism Gly54Asp (rs1800450) of the mannose‐binding lectin 2 gene might affect the mannose‐binding lectin serum level and recurrent aphthous stomatitis development. The aim of this study was to determine the distribution of six functional mannose‐binding lectin 2 gene polymorphisms and analyse their role in recurrent aphthous stomatitis susceptibility in the Czech population.Methods: The study included 227 subjects; 137 healthy people and 90 patients with recurrent aphthous stomatitis. Six mannose‐binding lectin 2 gene polymorphisms (rs11003125, rs7096206, rs7095891, rs5030737, rs1800450, rs1800451) were analysed by the SNaPshot assay method, mannose‐binding lectin serum levels were determined by enzyme‐linked immunosorbent assay (ELISA) method in a subgroup of subjects (N = 87).Results: No significant differences in mean of mannose‐binding lectin serum levels between healthy controls and patients with recurrent aphthous stomatitis were observed (383 ng/ml ± 249 standard deviation (SD) vs. 316 ng/ml ± 177 SD in remission phase vs. 343 ng/ml ± 254 SD in active phase;p > 0.05), also the allele and genotype frequencies of the studied mannose‐binding lectin 2 polymorphisms did not differ significantly between the two groups (p > 0.05, odds ratio (OR): 0.75–1.23). Moreover, the distribution of mannose‐binding lectin 2 haplotypes and haplogenotypes was similar in the healthy subjects and patients with recurrent aphthous stomatitis (p > 0.05, OR: 0.75–1.23).Conclusions: This study did not confirm the previously reported association of the mannose‐binding lectin 2 Gly54Asp gene variant and low mannose‐binding lectin serum level as the risk factors for susceptibility to recurrent aphthous stomatitis. In addition, no significant relationships between mannose‐binding lectin 2 functional haplotypes or haplogenotypes and recurrent aphthous stomatitis were observed.


  • Identification of telehealth nursing approaches in the light of the COVID‐19 pandemic—A literature review

    by Petra Búřilová, Andrea Pokorná, Jiří Búřil, Lucia Kantorová, Simona Slezaková, Zuzana Svobodová, Miloš Táborský

    Aims This study aimed to identify recommendations for quality nursing care provision, focusing on the possibilities of delivering telehealth nursing at the national level in the Czech Republic. Background The significant growth in the use of technology in health care has changed the environment for patient care and how health care is provided. The COVID-19 pandemic has shown the requirement for telemedicine use in everyday clinical practice. Evaluation A literature review aims to find guidelines, recommendations, manuals, standards or consensus papers published in 2017-2022. Key Issues In total, 12 guidelines were identified. Based on a critical evaluation carried out by two experts, the World Health Organization guideline focused on digital interventions to strengthen the health system has been identified. This guideline was evaluated to be of the highest quality and in line with the Grading of Recommendations, Assessment, Development and Evaluations methodology. Conclusion The provision of telemedicine nursing interventions is currently limited at the national level and is not entirely accepted in reimbursement yet. The interprofessional collaboration will be initiated to make recommendations for specific patient groups. Implications for Nursing Management Selected guidelines can be recommended for national adoption to set up and support nursing interventions in telemedicine, including nursing management settings.


  • Open Access

    Addressing Challenges When Applying GRADE to Public Health Guidelines: A Scoping Review Protocol and Pilot Analysis

    by Lucia Kantorová, Tereza Friessová, Simona Slezáková, Alena Langaufová, Jiří Kantor, Zachary Munn, Timothy Hugh Barker, Srinivasa Vittal Katikireddi, Reem A. Mustafa, Marija Franka Žuljević, et al.

    This is a protocol for a scoping review that aims to determine how guideline authors using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach have addressed previously identified challenges related to public health. The Joanna Briggs Institute (JBI) methodology for scoping reviews will be followed. We will search and screen titles of guidelines for all languages published in 2013–2021 in: the GIN library, BIGG database, Epistemonikos GRADE guidelines repository, GRADEpro Database, MAGICapp, NICE and WHO websites. Two reviewers will independently screen full texts of the documents identified. The following information will be extracted: methods used for identifying different stakeholders and incorporating their perspectives; methods for identification and prioritization of non-health outcomes; methods for determining thresholds for decision-making; methods for incorporating and grading evidence from non-randomized studies; methods for addressing concerns with conditional recommendations in public health; methods for reaching consensus; additional methodological concerns; and any modifications made to GRADE. A combination of directed content analysis and descriptive statistics will be used for data analysis, and the findings presented narratively in a tabular and graphical form. In this protocol, we present the pilot results from 13 identified eligible guidelines issued between January and August 2021. We will publish the full review results when they become available.


  • Open Access

    COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping

    by Salman Hussain, Harveen Baxi, Abanoub Riad, Jitka Klugarová, Andrea Pokorná, Simona Slezáková, Radim Líčeník, Abul Kalam Najmi, Miloslav Klugar

    Mucormycosis, a serious and rare fungal infection, has recently been reported in COVID-19 patients worldwide. This study aims to map all the emerging evidence on the COVID-19-associated mucormycosis (CAM) with a special focus on clinical presentation, treatment modalities, and patient outcomes. An extensive literature search was performed in MEDLINE (Ovid), Embase (Ovid), Cochrane COVID-19 Study Register, and WHO COVID-19 database till 9 June 2021. The primary outcome was to summarize the clinical presentation, treatment modalities, and patient outcomes of CAM. Data were summarized using descriptive statistics and presented in tabular form. This evidence mapping was based on a total of 167 CAM patients with a mean age of 51 ± 14.62 years, and 56.28% of them were male. Diabetes mellitus (73.65% (n = 123)), hypertension (22.75% (n = 38)), and renal failure (10.77% (n = 18)) were the most common co-morbidities among CAM patients. The most common symptoms observed in CAM patients were facial pain, ptosis, proptosis, visual acuity, and vision loss. Survival was higher in patients who underwent both medical and surgical management (64.96%). Overall mortality among CAM patients was found to be 38.32%. In conclusion, this study found a high incidence of CAM with a high mortality rate. Optimal glycemic control and early identification of mucormycosis should be the priority to reduce the morbidity and mortality related to CAM.


  • Open Access

    Oral ulcers of COVID-19 patients: a scoping review protocol

    by Abanoub Riad, Julien Issa, Veronika Chuchmova, Simona Slezakova, Esraa Gomaa, Andrea Pokorna, Jitka Klugarova, Miloslav Klugar

    Objective: This scoping review aims to systematically identify the types, characteristics, and possible pathophysiologic etiologies of the oral ulcers that emerge in COVID-19 patients. Introduction: The oral cavity is a vulnerable niche for the most diverse microbial ecosystem in the human body; therefore, it presents a wide array of mucocutaneous complications that could indicate various acute and chronic conditions. The COVID-19-related oral conditions, including oral ulcers, had been widely debated as direct manifestations or indirect complications of the SARS-CoV-2 infection. According to a preliminary search of PROSPERO, MEDLINE, the Cochrane Database of Systematic Reviews and the JBI Evidence Synthesis , there is no published nor registered scoping review concerned with the oral ulcers of COVID-19 patients. Inclusion criteria: The review will include studies included COVID-19 patients whose infection had been confirmed by RT-PCR testing regardless of infection severity and clinical course. Only the studies that reported COVID-19 patients with oral ulcers. Methods: A three-phase search strategy will be carried out: an initial limited search, a full electronic search, and hand search using the reference lists of all included records. The main bibliographic databases of published literature will include MEDLINE® (Ovid), EMBASE (Elsevier), and Cochrane COVID-19 Study Register. All identified records will be managed using EndNote 9.2, and the titles and abstracts will be screened against the inclusion criteria before the full text of all potentially relevant studies will be examined. The data will be presented in tabular form, rating maps, and narrative summary. Registration: This protocol had been pre-registered in Open Science Framework (OSF) Registries. [1]


  • Serotonin transporter gene (SLC6A4) variability in patients with recurrent aphthous stomatitis

    by Simona Slezakova, Petra Borilova Linhartova, Jirina Bartova, Jitka Petanova, Pavel Kuklinek, Antonin Fassmann, Lydie Izakovicova Holla


  • Gene variability in matrix metalloproteinases in patients with recurrent aphthous stomatitis

    by Simona Slezakova, Petra Borilova Linhartova, Jirina Bartova, Jitka Petanova, Pavel Kuklinek, Antonin Fassmann, Ladislav Dusek, Lydie Izakovicova Holla

    Background The development of recurrent aphthous stomatitis (RAS), inflammatory disease of oral mucosa, is influenced by both environmental and genetic factors. The aim of this study was to investigate polymorphisms located in seven genes coding different types of matrix metalloproteinases (MMPs) ‐ collagenases (MMP1, MMP8, MMP13), gelatinases (MMP2, MMP9), stromelysin (MMP3), and membrane type metalloproteinase (MMP16) in patients with RAS and healthy controls. Methods Totally, 226 subjects were included in this case‐control study and their detailed anamnestic, clinical and laboratory parameters were recorded. 77 patients with RAS and 146 controls were genotyped for seventeen polymorphisms in the MMPs genes using the Real‐Time polymerase chain reaction (PCR) or PCR with restriction analysis. Results Allele, genotype and haplotype frequencies of the studied polymorphisms between RAS patients and controls were similar, except for allele distributions of MMP1 rs1144393, MMP9 rs3918242, and MMP16rs10429371, which were different between patients with RAS and healthy controls (P=0.024, P=0.049 and P=0.026, all Pcorr>0.05, respectively). Moreover, the comparison of genotype frequencies (TT vs. CC+CT) of the MMP16 rs10429371 variant showed a marginally significant difference between RAS patients and controls (P=0.05, Pcorr>0.05, OR=1.68, 95%CI =0.95‐2.98). Conclusions No significant relationship between investigated polymorphisms in seven MMPs genes and RAS development in the Czech population was observed in this study.


  • Recurrent aphthous stomatitis and gene variability in selected interleukins: a case–control study

    by Petra Borilova Linhartova, Julius Janos, Simona Slezakova, Jirina Bartova, Jitka Petanova, Pavel Kuklinek, Antonin Fassmann, Ladislav Dusek, Lydie Izakovicova Holla

    Genetic factors, especially those related to immune system functioning, have been intensively studied to determine their role in the development of recurrent aphthous stomatitis (RAS). The aim of the present study was to analyze gene variability in interleukin (IL)2, IL4 (and its receptor α, IL4Rα), IL10, and IL13, which were selected based on literature review and/or their functional relevance, in Czech patients with RAS and in healthy controls. In total, 252 subjects (178 controls and 74 patients with RAS) were enrolled in this case–control study, and their detailed anamnestic, clinical, and laboratory data were obtained. Nine polymorphisms in the genes encoding interleukins were determined using PCR techniques. There were no significant differences in allele or genotype frequencies of the IL2, IL4, IL4Rα, IL10, and IL13 polymorphisms rs2069762/rs2069763, rs2243250/rs79071878, rs1801275, rs1800896, and rs1800925, respectively, between controls and patients with RAS. The minority alleles rs1800871 and rs1800872, which encode variants of IL10, were associated with a statistically significantly higher risk of RAS, as confirmed by the results of genotype and haplotype analyses. We suggest that variability in the IL10 gene may play an important role in the development of RAS in the Czech population.


  • Association of the NOD‐like receptor 3 (NLRP3) gene variability with recurrent aphthous stomatitis in the Czech population

    by Simona Slezakova, Petra Borilova Linhartova, Lucie Masopustova, Jirina Bartova, Jitka Petanova, Pavel Kuklinek, Antonin Fassmann, Ladislav Dusek, Lydie Izakovicova Holla

    Background: Recurrent aphthous stomatitis (RAS) is a multifactorial disease with unclear etiopathogenesis in which disturbance of immunological processes may be involved. The aim of our study was to investigate three single nucleotide polymorphisms (SNPs) rs3806265, rs4612666, rs10754558 in NOD‐like receptor 3 (NLRP3), the gene encoding the component of inflammasome, in patients with RAS and healthy controls in the Czech population.Methods: A total of 207 subjects were included in this case‐control study. Sixty‐four patients with RAS and 143 healthy controls were genotyped by a method based on polymerase chain reaction using 5′ nuclease TaqMan® assays. Detailed anamnestic, clinical, and laboratory data were obtained from all subjects.Results: The allele and genotype frequencies of NLRP3 polymorphisms (rs10754558 and rs3806265) between both groups were similar. However, statistically significant differences in NLRP3 rs4612666 genotypes between the patients with RAS and controls were found; carriers of the TT genotype had a higher risk of developing RAS than subjects with the CT+CC genotypes (OR = 14.69, 95%CI = 1.73‐124.72, P = .004, Pcorr < .05). No associations between NLRP3 haplotypes and RAS were observed.Conclusions: Our study indicates that the NLRP3 rs4612666 polymorphism may be involved in the development of RAS in the Czech population.